Skip to main content

Table 2 Patient baseline characteristics of NPC patients after PSM

From: Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

Characteristic NTZ group
N = 50 (%)
Non-NTZ group
N = 50 (%)
P value
Gender 0.856
 Male 34 (68.00) 66 (66.00)  
 Female 16 (32.00) 34 (34.00)  
Age 1.00
 ≤ 50 33 (66.00) 66 (66.00)  
 > 50 17 (34.00) 34 (34.00)  
T classification 0.937
 T1 6 (12.00) 11 (11.00)  
 T2 7 (14.00) 10 (10.00.)  
 T3 20 (40.00) 48 (48.00)  
 T4 17 (34.00) 31 (31.00)  
N classification 0.925
 N0 3 (6.00) 9 (9.00)  
 N1 17 (34.00) 28 (28.00)  
 N2 18 (36.00) 42 (42.00)  
 N3 12 (24.00) 21 (21.00)  
Clinical stage 0.565
 III 23 (46.00) 51 (51.00)  
 IV 27 (54.00) 49 (49.00)